KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortizatization of Intangibles (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Amortizatization of Intangibles for 13 consecutive years, with $73.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 3883.84% to $73.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.7 million, a 39.05% increase, with the full-year FY2025 number at $76.7 million, up 943.02% from a year prior.
  • Amortizatization of Intangibles was $73.5 million for Q4 2025 at Halozyme Therapeutics, up from -$16.4 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $73.5 million in Q4 2025 to a low of -$49.7 million in Q4 2023.
  • A 5-year average of $9.6 million and a median of $7.5 million in 2021 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: plummeted 598.61% in 2023, then skyrocketed 3883.84% in 2025.
  • Halozyme Therapeutics' Amortizatization of Intangibles stood at $3.6 million in 2021, then crashed by 295.3% to -$7.1 million in 2022, then tumbled by 598.61% to -$49.7 million in 2023, then surged by 103.71% to $1.8 million in 2024, then surged by 3883.84% to $73.5 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Amortizatization of Intangibles are $73.5 million (Q4 2025), -$16.4 million (Q3 2025), and $17.8 million (Q2 2025).